SYHX1901 clinical trials
Also written SYHX1901.
How each study uses SYHX1901 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the SYHX1901 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- SYHX1901
- 4
Studies by the year they started
5 studies that test it; most in 2025 (2)
| Year | Studies |
|---|---|
| 2021 | 1 |
| 2023 | 1 |
| 2024 | 1 |
| 2025 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 5 · Other 0
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 2, 1 in phase 3
Studies that test SYHX1901, phase 3 first.
- Apr 2027A Phase III Study of SYHX1901 Tablets in the Treatment of Moderate to Severe Plaque PsoriasisPhase 3 · CSPC Ouyi Pharmaceutical Co., Ltd.
- May 2027Study to Evaluate Safety and Efficacy of SYHX1901 Tablets in Severe Alopecia Areata PatientsPhase 2 · CSPC Ouyi Pharmaceutical Co., Ltd.
Studies
Open first, then newest update. How each study uses SYHX1901 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 5
- Study to Evaluate Safety and Efficacy of SYHX1901 Tablets in Severe Alopecia Areata PatientsNot yet recruitingPhase 2CSPC Ouyi Pharmaceutical Co., Ltd.NCT06562894Written as SYHX1901
- A Phase III Study of SYHX1901 Tablets in the Treatment of Moderate to Severe Plaque PsoriasisNot yet recruitingPhase 3CSPC Ouyi Pharmaceutical Co., Ltd.NCT06943950Written as SYHX1901
- A Study to Evaluate the Efficacy and Safety of SYHX1901 Tablet in Non-segmental Vitiligo PatientsRecruitingPhase 2CSPC Ouyi Pharmaceutical Co., Ltd.NCT06511739Written as SYHX1901
- An Investigational Study to Evaluate Experimental Medication SYHX1901 Tablets With Moderate to Severe Plaque PsoriasisCompletedPhase 2CSPC Ouyi Pharmaceutical Co., Ltd.NCT05858047Written as SYHX1901
- The Safety, Tolerability, and Pharmacokinetics of SYHX1901 Tablets in Chinese Healthy SubjectsStatus unknownPhase 1CSPC Ouyi Pharmaceutical Co., Ltd.NCT04880512Written as SYHX 1901 tablets